Abattis Bioceuticals is a public company traded on the CSE in Canada and through the OTC market in the United States.

Abattis Bioceuticals Corp. is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols and adheres to applicable laws of Canada and foreign jurisdictions

Principal Subsidiaries:

Vergence Naturals
Gabriola Green Farms Inc
Green Tree Therapeutics Inc.

Strategic Partnerships:

CannaNUMUS Blockchain Inc.
XLabs Therapeutics Inc

Stock Exchanges and Trading:

OTC (United States): ATTBF
CSE (Canada): ATT

Latest Company filings can be found on SEDAR

Fiscal Year End: 9/30
SIC – Industry Class: 2833 – medicinal and botanicals
Incorporated In: British Columbia, Canada
Year of Inc.: 1997


  • Robert Abenante – President & CEO
  • Francesco Paolini – CFO
  • Patrick Mitchell – COO



  • Robert Abenante – Director
  • Francesco Paolini – Director
  • Peter Gordon – Director
  • Cedric Wilson – Director



NVS Chartered Accountants Professional Corporation


Legal Counsel

Clark Wilson LLP


Transfer Agent

Computershare Investor Services Inc.